Business Wire

Milrem Robotics rullar ut sitt nya robotstridsfordon Type-X

Dela

Robotstridsfordonet Type-X i mellanklassen från den ledande europeiska utvecklaren av robot- och autonoma system, Milrem Robotics, har klarat sina inledande mobilitetstester.

Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20210112005546/sv/

Type-X från Milrem Robotics kommer att bli en intelligent andrepilot för huvudstridsvagnar och infanteristridsfordon och kommer att kunna ta sig an de farligaste uppgifterna och positionerna, vilket leder till lägre dödsrisker. (Foto: Business Wire)

Type-X från Milrem Robotics kommer att bli en intelligent andrepilot för huvudstridsvagnar och infanteristridsfordon och kommer att kunna ta sig an de farligaste uppgifterna och positionerna, vilket leder till lägre dödsrisker. (Foto: Business Wire)

Type-X kommer att bli en intelligent andrepilot för huvudstridsvagnar och infanteristridsfordon och kommer att kunna ta sig an de farligaste uppgifterna och positionerna, vilket leder till lägre dödsrisker.

“Type-X kommer att ge lika eller överträffande eldkraft och taktisk användning till en enhet utrustad med infanteribekämpningsfordon. Det ger medel att bryta igenom fiendens defensiva positioner med minimal risk för egna trupper och att ersätta ett förlorat robotstridsfordon är ett rent logistiskt besvär”, förklarar Kuldar Väärsi, VD för Milrem Robotics.

Type-X kan utrustas med en kanon på upp till 50 mm. Med en kanon på upp till 30 mm kan robotstridsfordonet släppas från luften - C-130J och KC-390 kan bära ett, A400M två och ett C-17 fem.

“Fordonet kommer att vara utrustat med intelligenta funktioner som t.ex. följ-mig, waypoint-navigering och hinderdetektering med artificiell intelligens som en del av algoritmerna”, säger Väärsi. “Våra programutvecklare har också tagit ett helt nytt och innovativt tillvägagångssätt för att möjliggöra fjärrstyrd drift i högre hastigheter.”

Med en vikt på 12 ton och effektiv energihantering har fordonet överlägsen terrängförmåga. Dess höjd på 2,2 m och bakre motor ger låg värme- och visuell signatur.

Type-X är tre till fyra gånger lättare och dess kostnad avsevärt lägre än för ett konventionellt infanteristridsfordon. Det har utformats med intelligent prediktivt underhåll kombinerat med ett system för övervakning av hälsa och användning och ersättningsprincip för linjeenhet för att säkerställa en låg kostnad genom livscykeln och logistiskt fotavtryck. Dess hybrida drivlina och gummilarvband minskar livscykelkostnaderna avsevärt.

För att skapa Type-X har Milrem Robotics använt sin kunskap från att utveckla sitt obemannade markfordon THeMIS, avsett att stödja frigående trupper, som har förvärvats av tio länder, inklusive sju NATO-medlemmar: Frankrike, Norge, Storbritannien, USA, Tyskland, Nederländerna och Estland.

Milrem Robotics är Europas ledande utvecklare av robot- och autonoma system med två kontor i Estland, ett i Sverige och Finland och inom kort ett i Nederländerna.

Företaget leder ett konsortium som tilldelats 30,6 miljoner euro från Europeiska kommissionens European Defense Industrial Development Program (EDIDP) för att utveckla ett europeiskt standardiserat obemannat marksystem.

Titta på videon om Type-X: https://youtu.be/34-NWYQ0L0c

Contact information

Gert Hankewitz
Exportchef
Gert.hankewitz@milrem.com

Om

Business Wire
Business Wire



Följ Business Wire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum